Degradation Pathways of a Corticotropin-Releasing Factor Antagonist in Solution and Solid States

被引:3
|
作者
Badawy, S. [1 ]
Hussain, M. [1 ]
Zhao, F. [1 ]
Ye, Q. [1 ]
Huang, Y. [1 ]
Palaniswamy, V. [1 ]
机构
[1] Bristol Myers Squibb Co, Pharmaceut Dev, New Brunswick, NJ 08903 USA
关键词
chemical stability; stability; solid state stability; stabilization; solid dosage form; HYDROLYSIS;
D O I
10.1002/jps.21637
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Stability of the 1,3,5-triazine derivative (1), a corticotropin-releasing factor inhibitor, was studied in acidic solutions and in solid formulations. Degradant structures were elucidated using liquid chromatography/mass spectrometry (LC/MS) and nuclear magnetic resonance (NMR). Compound I was found to undergo hydrolysis via two pathways. Pathway 1 involves three hydrolysis steps of the triazine ring. Pathway 2 proceeds through hydroxy substitution of the amino group on the triazine ring followed by its hydrolysis, eventually resulting in the formation of the same degradant as pathway 1. Stability of 1 in the tablets was dependent on the manufacturing process and degradation appeared to proceed more rapidly in amorphous regions created during processing. Pathways 1 and 2 were observed in the tablets and degradation rate was enhanced at. high humidity condition. In addition to pathways I and 2, degradation in the tablet formulations was found to proceed through a third pathway involving nucleophilic displacement of the ether methoxy group by the triazine N-3. The resulting imidazolidinium intermediate was found to undergo a series of hydrolytic steps finally leading to the same end degradant as pathways 1 and 2. This intermediate was observed at a lower concentration in the tablet at the high humidity conditions and at very low concentrations in acidic solutions. (C) 2008 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 98:2636-2647, 2009
引用
收藏
页码:2636 / 2647
页数:12
相关论文
共 50 条
  • [41] [D-Pro(5)]corticotropin-releasing factor analogs as selective agonists at corticotropin-releasing factor receptors
    Wei, ET
    Thomas, HA
    Price, JS
    Kishimoto, T
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 306 (1-3) : 161 - 164
  • [42] Corticotropin-Releasing Factor Acting on Corticotropin-Releasing Factor Receptor Type 1 is Critical for Binge Alcohol Drinking in Mice
    Kaur, Simranjit
    Li, Ju
    Stenzel-Poore, Mary P.
    Ryabinin, Andrey E.
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2012, 36 (02) : 369 - 376
  • [43] The potential role of a corticotropin-releasing factor receptor-1 antagonist in psychiatric disorders
    Stahl, Stephen M.
    Wise, Dana D.
    CNS SPECTRUMS, 2008, 13 (06) : 467 - +
  • [44] Both corticotropin-releasing factor and apomorphine reduce prepulse inhibition following repeated central infusion of corticotropin-releasing factor
    Conti, Lisa H.
    Berridge, Craig W.
    Tayler, Jane E.
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2006, 85 (01) : 261 - 272
  • [45] EFFECTS OF PRETREATMENT WITH CORTICOTROPIN-RELEASING FACTOR ON THE ELECTROPHYSIOLOGICAL RESPONSIVITY OF THE LOCUS-COERULEUS TO SUBSEQUENT CORTICOTROPIN-RELEASING FACTOR CHALLENGE
    CONTI, LH
    FOOTE, SL
    NEUROSCIENCE, 1995, 69 (01) : 209 - 219
  • [46] Toxicity of Pexacerfont, a Corticotropin-Releasing Factor Type 1 Receptor Antagonist, in Rats and Dogs
    White, Melvin R.
    Graziano, Michael J.
    Sanderson, Thomas P.
    INTERNATIONAL JOURNAL OF TOXICOLOGY, 2019, 38 (02) : 110 - 120
  • [47] Binding Kinetics Redefine the Antagonist Pharmacology of the Corticotropin-Releasing Factor Type 1 Receptor
    Fleck, Beth A.
    Hoare, Sam R. J.
    Pick, Rebecca R.
    Bradbury, Margaret J.
    Grigoriadis, Dimitri E.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2012, 341 (02): : 518 - 531
  • [48] Comparison of an agonist, urocortin, and an antagonist, astressin, as radioligands for characterization of corticotropin-releasing factor receptors
    Perrin, MH
    Sutton, SW
    Cervini, LA
    Rivier, JE
    Vale, WW
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1999, 288 (02): : 729 - 734
  • [49] POTENTIATION BY VASOPRESSIN OF CORTICOTROPIN RELEASE INDUCED BY CORTICOTROPIN-RELEASING FACTOR
    YATES, FE
    RUSSELL, SM
    DALLMAN, MF
    HEDGE, GA
    MCCANN, SM
    DHARIWAL, AP
    ENDOCRINOLOGY, 1971, 88 (01) : 3 - +
  • [50] Stress, corticotropin-releasing factor, and drug addiction
    Koob, GF
    NEUROPEPTIDES: STRUCTURE AND FUNCTION IN BIOLOGY AND BEHAVIOR, 1999, 897 : 27 - 45